Multiple Sclerosis Clinical Trial
Official title:
Measuring the Effect of Using the Arabic Otago Exercise Program on Falls and Falls-related Factors in People With Multiple Sclerosis
NCT number | NCT04818008 |
Other study ID # | "11-2021" |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2022 |
Est. completion date | June 30, 2023 |
Verified date | July 2023 |
Source | University of Jordan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
People with multiple sclerosis (MS) need exercise training programs throughout their life in order to prevent secondary complications of the disease. Coronavirus disease of 2019 (COVID-19) forced people with chronic disorders to stay at home in order to prevent the transmission of the virus. Therefore, people with MS now are facing a new challenge in going outside their home to perform their rehabilitation sessions. One of the solutions to keep them exercising is a home-based exercise program and one of the home exercise programs that are well validated in older adults is the Otago exercise program (OEP). Investigators suggest that the balance would improve and fall incidences would reduce using the OEP in people with MS compared to health awareness videos only. 50 participants with confirmed diagnosis of MS will be recruited in both groups. Using a randomized controlled trial this study aims to examine the effectiveness of the OEP compared to a control group that gets health awareness videos only on falls and falls-related factors in people with MS.
Status | Completed |
Enrollment | 73 |
Est. completion date | June 30, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age of 18 years and older. 2. Both genders 3. All types of multiple sclerosis. 4. Independent in ambulation even with the use of an assistive device. 5. An Expanded Disability Status Scale (EDSS) score = 6.5. Exclusion Criteria: 1. The diagnosis of other neurological or musculoskeletal disorders that affect balance. 2. If the patient had a relapse within that last four weeks. 3. wheelchair users. 4. If the patient is engaged in any exercise program. |
Country | Name | City | State |
---|---|---|---|
Jordan | University of Jordan | Amman |
Lead Sponsor | Collaborator |
---|---|
University of Jordan |
Jordan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of falls | The effect of the intervention on the incidence of falls. | 2 months post intervention. | |
Primary | Incidence of falls | The effect of the intervention on the incidence of falls. | 6 months post intervention. | |
Primary | Incidence of falls | The effect of the intervention on the incidence of falls. | 12 months post intervention. | |
Secondary | Fear of Falling (using the Falls Efficacy Scale-International ) | The effect of the intervention on fear of falling. The total score ranges between 16 and 64 with a higher score indicates greater fear of falling (worse). | 2 months post intervention. | |
Secondary | Balance (using Chair balance test and Four test balance scale) | The effect of the intervention on balance. The time taken to conduct these balance tasks are timed using a stopwatch. The longer the time taken by the patient to perform the tasks, the worse the balance. There is no minimum or maximum scores for these tests. | 2 months post intervention. | |
Secondary | Mobility (using Timed-Up and go) | The effect of the intervention on mobility. This assessments of mobility is timed out using a stopwatch. | 2 months post intervention. | |
Secondary | Quadriceps strength (using a dynamometer) | The effect of the intervention on quadriceps strength. The strength of quadriceps will be assessed using a dynamometer in kilograms. | 2 months post intervention. | |
Secondary | The severity of fatigue (using Modified Fatigue Impact Scale) | The effect of the intervention on the severity of fatigue. The total score ranges from 0 to 84 with a higher score indicates greater severity of fatigue symptoms (worse). | 2 months post intervention. | |
Secondary | the Quality of sleep (Using Pittsburgh Sleep Quality Index) | The effect of the intervention on the Quality of sleep. The total score ranges from 0 to 21 with a higher score indicates poor quality of sleep (worse). | 2 months post intervention. | |
Secondary | the severity of Anxiety and Depression (using Hospital Anxiety and Depression Scale) | The effect of the intervention on the severity of Anxiety and Depression. The total score for each subscale of the HADS ranges from 0 to 21 with higher score indicates more severe anxiety or depression (worse). | 2 months post intervention. | |
Secondary | The Quality of Life (using Medical Outcomes Study Short Form 12) | The effect of the intervention on Quality of Life. The total score ranges between 0% to 100% with higher score indicates a better quality of life (better). | 2 months post intervention. | |
Secondary | Cognitive ability (using Montreal Cognitive Assessment) | The effect of the intervention on Cognitive ability. The total score ranges from 0 to 30 points with a score of 25 or less indicating cognitive impairment (worse). | 2 months post intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |